Cat. No. | Product name | CAS No. |
DC42670 |
BMS-191011
Featured
BMS 191011 is an activator of large-conductance calcium-activated potassium (BKCa) channels that increases maximum potassium current to 126% of control in X. laevis oocytes expressing human BKCa channels when used at a concentration of 1 μM. |
202821-81-6 |
DC42671 |
Galloflavin
Featured
Novel inhibitor of lactate dehydrogenase |
568-80-9 |
DC42681 |
FABP4/5-IN-2
Featured
Novel FABP4/5 inhibitor, inhibiting lipolysis in 3T3-L1 adipocytes and in primary human adipocytes |
1227413-92-4 |
DC42686 |
AVE-9488
Featured
Novel enhancer of endothelial NO synthase (eNOS) |
291756-32-6 |
DC42691 |
Synucleozid dihydrochloride
Featured
Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the SNCA mRNA that encodes alpha-synuclein protein (IC50=1.5 uM). Synucleozid selectively targets the alpha-synuclein mRNA 5? UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson's disease[1]. IC50 & Target: IC50: 1.5 uM (SNCA IRE RNA)[1] In Vitro: Synucleozid (0.25-1 uM; 24 hours) abrogates cytotoxicity induced by alpha-synuclein preformed fibrils, which act as seeds and recruit endogenous alpha-synuclein to aggregate[1]. Synucleozid (0-1 uM; 24 hours) binds to the A bulge near the base of the IRE hairpin, reduced levels of alpha-synuclein in a dose-dependent manner with an IC50 of 500 nM, and inhibits alpha-synuclein protein expression in SH-SY5Y neuroblastoma cells[1]. Synucleozid (100 nM-100 uM; 24 hours) binds to 2-AP-labeled and native IRE RNA with similar affinities. It decreases 2-AP emission with an EC50 value of 2.7 uM, recovery of 2-AP emissions is observed as a function of unlabeled SNCA IRE RNA (RNA-0) concentration, affording a competitive Kd of 1.5 uM[1]. Synucleozid (0.25-1 uM; 24 hours) decreases alpha-synuclein and other proteins that have IREs in their mRNA's UTR including APP, PrP, Ferritin and TfR as a dose-dependent mannner. All panels is completed in SH-SY5Y cells, except for PrP protein which is assessed in Neuro-2A cells[1]. |
502139-01-7 |
DC42693 |
CL5D
Featured
Novel potent SIRT6 activator against whole histone substrate |
|
DC42697 |
RBPJ Inhibitor-1 (RIN1)
Featured
RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation. |
2682114-39-0 |
DC42700 |
MGH-CP1
Featured
MGH-CP1 is a potent and selective TEAD palmitoylation inhibitor. |
896657-58-2 |
DC42705 |
BRD0418
Featured
Novel upregulator of TRIB1 expression, leading to reprogramming of hepatic lipoprotein metabolism from lipogenesis to scavenging |
1565827-99-7 |
DC42708 |
AZ3976
Featured
Novel inhibitor of plasminogen activator inhibitor type 1 (PAI-1) |
1418747-15-5 |
DC42709 |
GSK3987
Featured
Potent and specific liver X receptor (LXR) dual agonist of LXRalpha and LXRbeta |
264206-85-1 |
DC42710 |
F5446
Featured
F5446 is a SUV39H1 inhibitor. F5446 has an EC50 of 0.496 μmol/L for SUV39H1 enzymatic activity. H3K9me3 was enriched in the promoters of GZMB, PRF1, FASLG, and IFNG in quiescent T cells. F5446 inhibited H3K9me3, thereby upregulating expression of these effectors in tumor-infiltrating CTLs and suppressing colon carcinoma growth in a CD8+ CTL-dependent manner in vivo. Our data indicate that SUV39H1 represses CTL effector gene expression and, in doing so, confers colon cancer immune escape. |
2304465-89-0 |
DC42712 |
10-Cl-BBQ
Featured
Potent aryl hydrocarbon receptor (AhR) ligand |
23982-76-5 |
DC42713 |
CS-2100
Featured
Potent, orally active and S1P3-sparing S1P1 agonist |
913827-99-3 |
DC42714 |
BMS-8
Featured
BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1[1]. |
1675201-90-7 |
DC42715 |
SR-16584
Featured
SR 16584 is a selective antagonist of α3β4 nAChR with an IC50 of 10.2 μM. |
1150153-86-8 |
DC42718 |
G150
Featured
G150 is a highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with an IC50 of 10.2 nM. G150 represses dsDNA-triggered interferon expression, and G150 can be used for the research of inflammatory. |
2369751-30-2 |
DC42720 |
G140
Featured
G140 is a potent and selective inhibitor of cyclic GMP-AMP synthase (cGAS), with IC50s of 14.0 nM and 442 nM for h-cGAS and m-cGAS, respectively. G140 has anti-inflammatory activity. |
2369751-07-3 |
DC42721 |
NCGC2955
Featured
Novel Inhibitor of Human Cytomegalovirus (HCMV) |
|
DC42722 |
NSC47924
Featured
Novel 37/67kDa laminin receptor (LR) inhibitor, affecting both the direct 37/67kDa LR-PrP(C) interaction in vitro and the formation of the immunocomplex in live cells, inducing a progressive internalization of 37/67kDa LR and stabilization of PrP(C) on th |
6638-24-0 |
DC42723 |
GSK840
Featured
Novel potent and selective RIP3 kinase inhibitor |
2361146-30-5 |
DC42724 |
ML211
Featured
Dual inhibitor for lysophospholipase 1 (LYPLA1) and lysophospholipase 2 (LYPLA2) |
2205032-89-7 |